Sionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 115,844 Shares

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 115,844 shares of the business’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the completion of the transaction, the director owned 2,555,877 shares in the company, valued at $116,292,403.50. This represents a 4.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Price Performance

Shares of Sionna Therapeutics stock opened at $43.99 on Friday. The business has a 50-day moving average of $39.83 and a 200-day moving average of $39.50. The company has a market capitalization of $1.99 billion, a PE ratio of -22.79 and a beta of 1.33. Sionna Therapeutics, Inc. has a 1-year low of $16.38 and a 1-year high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). On average, equities analysts expect that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Eventide Asset Management LLC acquired a new position in Sionna Therapeutics in the fourth quarter worth $26,290,000. Vanguard Group Inc. raised its holdings in shares of Sionna Therapeutics by 81.4% during the third quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock worth $33,620,000 after purchasing an additional 512,803 shares during the period. State Street Corp raised its holdings in shares of Sionna Therapeutics by 188.7% during the fourth quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after purchasing an additional 453,196 shares during the period. Jennison Associates LLC lifted its position in shares of Sionna Therapeutics by 30.1% in the 1st quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock worth $58,179,000 after buying an additional 335,942 shares during the last quarter. Finally, Viking Global Investors LP lifted its position in shares of Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after buying an additional 242,427 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SION shares. JonesTrading upped their target price on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. BTIG Research restated a “buy” rating and issued a $58.00 price target on shares of Sionna Therapeutics in a research note on Wednesday, May 13th. Stifel Nicolaus upped their price target on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a report on Monday, May 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Finally, Wedbush assumed coverage on shares of Sionna Therapeutics in a report on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $53.22.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.